Kryxana 200mg Tablet contains ribociclib 200mg, a prescription CDK4/6 inhibitor used as targeted therapy for adults with hormone receptor-positive (HR+), HER2-negative breast cancer. Ribociclib is marketed as Kryxana in several markets and as Kisqali® in others. It is used in combination with endocrine therapy for eligible patients with early, locally advanced, or metastatic breast cancer according to the applicable regulatory indication.
The 200mg tablet is an important strength of ribociclib and can form part of the prescribed daily dose or be used for dose modification when clinically indicated. In the U.S., the approved regimen for HR+/HER2− early breast cancer is 400mg once daily (two 200mg tablets) for 21 days followed by 7 days off, while advanced or metastatic disease generally uses 600mg once daily (three 200mg tablets) for 21 days followed by 7 days off.
Kryxana should be prescribed and monitored by a healthcare professional experienced in cancer treatment.
Kryxana 200mg is an oral targeted cancer medicine containing ribociclib.
Ribociclib belongs to the CDK4/6 inhibitor class. These medicines interfere with proteins called cyclin-dependent kinases 4 and 6, which are involved in regulating progression through the cell cycle.
By inhibiting CDK4/6 activity, ribociclib can help slow the proliferation of certain breast cancer cells. It is particularly used in tumors that are hormone receptor-positive and HER2-negative.
Kryxana/ribociclib is used for eligible patients with HR-positive, HER2-negative breast cancer.
Depending on the applicable regulatory approval, uses include:
In pre- or perimenopausal patients, endocrine therapy may also require ovarian suppression with an LHRH agonist. Approved indications and treatment requirements vary by market.
Ribociclib selectively inhibits CDK4 and CDK6.
These enzymes normally help regulate the transition of cells from the G1 phase into the S phase of the cell cycle. Inhibition of CDK4/6 can prevent susceptible cancer cells from progressing through the cell cycle and multiplying.
This mechanism makes ribociclib a targeted cell-cycle therapy rather than a conventional cytotoxic chemotherapy.
Kryxana is primarily associated with treatment of HR-positive, HER2-negative breast cancer.
For advanced or metastatic disease, ribociclib is combined with endocrine therapy such as an aromatase inhibitor or fulvestrant depending on the clinical situation. In early breast cancer, ribociclib can be used with an aromatase inhibitor for eligible patients at increased risk of recurrence.
This creates the primary commercial search relationship:
Kryxana 200mg → Ribociclib 200mg → CDK4/6 Inhibitor → HR+/HER2− Breast Cancer → Targeted Breast Cancer Treatment
Kryxana® and Kisqali® contain the same active ingredient, ribociclib, but the brand name used can differ by market.
Kisqali is the Novartis brand name used in the United States and several other markets, while Kryxana is used in markets including parts of Asia. The exact product authorization, packaging and approved indications should always be checked for the relevant country.
Where an appropriately authorized equivalent or generic product is available, relevant commercial searches may include Ribociclib 200mg, Generic Ribociclib 200mg, Generic Kryxana 200mg, Generic Kisqali 200mg and Ribociclib 200mg Tablet.
The prescribed ribociclib dose depends on the indication, treatment combination, patient characteristics and tolerability.
For example, current U.S. prescribing information specifies:
Dose interruptions or reductions may be required because of adverse reactions or other clinical factors. The 200mg tablet may therefore be used as part of the prescribed dose or for dose modification.
Do not change the dosage or treatment schedule without instructions from the treating oncologist.
Ribociclib can cause adverse effects and requires medical monitoring.
Potential adverse reactions include:
Important serious risks include QT interval prolongation, hepatotoxicity and interstitial lung disease/pneumonitis. Patients should report symptoms such as fainting, abnormal heartbeat, breathing difficulties, persistent cough, fever or other concerning symptoms promptly to their healthcare provider.
Treatment with ribociclib requires appropriate oncology monitoring.
Depending on the treatment setting, healthcare professionals may monitor:
Ribociclib also has clinically important drug-interaction considerations, including interactions involving CYP3A inhibitors and inducers.
Kryxana 200mg Tablet is a prescription oncology medicine. Customers searching for Kryxana 200mg, Kryxana 200mg Tablet, Ribociclib 200mg, Buy Kryxana 200mg, Buy Ribociclib 200mg, Kryxana 200mg Price, Ribociclib 200mg Price, Generic Kryxana 200mg, Generic Kisqali 200mg and related transactional terms should obtain the medicine through an appropriately licensed pharmacy or authorized pharmaceutical supplier.
Availability, prescription requirements, approved indications, import regulations and dispensing requirements vary across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.
Kryxana contains ribociclib and is used with endocrine therapy for eligible HR-positive, HER2-negative breast cancer, including certain early, locally advanced or metastatic disease settings.
The generic name is ribociclib.
Both contain ribociclib 200mg. Kryxana and Kisqali are brand names used in different markets; the exact authorization and labeling should be checked for the country where the medicine is supplied.
Kryxana is a targeted CDK4/6 inhibitor, rather than a traditional cytotoxic chemotherapy drug.
Ribociclib is used for hormone receptor-positive (HR+), HER2-negative breast cancer in specific approved treatment settings.
Ribociclib blocks CDK4 and CDK6, proteins involved in cell-cycle progression. This can slow the multiplication of susceptible breast cancer cells.
The number of tablets depends on the indication and prescribed dose. Current U.S. labeling uses two 200mg tablets daily for certain early-breast-cancer treatment and three 200mg tablets daily for advanced or metastatic disease, followed by a 7-day treatment break in the 28-day cycle.
Yes. Ribociclib is used in combination with an aromatase inhibitor for several approved HR+/HER2− breast cancer indications.
Yes. Ribociclib is approved with fulvestrant for certain patients with HR+/HER2− advanced or metastatic breast cancer.
Kryxana is a prescription anticancer medicine. It should be purchased only through an appropriately licensed pharmacy or authorized pharmaceutical supplier and used under oncology supervision.
Yes. Blood counts, liver function, ECG/QT interval and other clinical parameters may require monitoring during treatment because ribociclib can cause significant adverse reactions.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Kryxana (ribociclib) is a prescription anticancer medicine that requires specialist medical supervision. Treatment selection, dosage, combination therapy, monitoring and approved indications depend on the patient’s cancer type, clinical status and applicable regulatory labeling. Ribociclib can cause serious adverse reactions, including neutropenia, liver toxicity, QT prolongation and interstitial lung disease/pneumonitis. Always follow the official prescribing information for the specific product and consult a qualified oncologist before starting, stopping or changing treatment.
Last Updated: August 23, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Only logged in customers who have purchased this product may leave a review.
Dalip Singh –
Items packed overnight, packages, sent with tracking. Thank you, it was very important for me.
Abdul Aziz –
Best product, best service and super fast delivery.